ClinConnect ClinConnect Logo
Search / Trial NCT03697785

Weaning Algorithm for Mechanical VEntilation

Launched by ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST · Oct 4, 2018

Trial Information

Current as of May 08, 2025

Unknown status

Keywords

Weaning Cardiothoracic Mechanical Ventilation Intensive Care Critical Care Beacon Caresystem

ClinConnect Summary

Patients admitted to the intensive care unit typically receive invasive mechanical ventilatory support when they are critically ill. Whilst mechanical ventilation is a life-saving intervention, it can also lead to deleterious consequences and cause lung damage (known as ventilator-associated lung injury) if not implemented carefully. Hence, reducing the duration of mechanical ventilation should reduce complications such as ventilator-associated lung injury, ventilator-acquired pneumonia, respiratory and skeletal muscle wasting, and patient discomfort, leading to decreasing mortality and eco...

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • Patient remains on mechanical ventilation at 24 hours following intubation.
  • Age \> 18 years
  • Patient consent or, in the case that the patient is unable, advice from the next of kin or treating physician following understanding and acceptance of oral and written information describing the study.
  • Exclusion criteria:
  • The absence of an arterial catheter for blood sampling at study start.
  • Mechanical ventilation initiated for more than 48 hours.
  • Medical history of home mechanical ventilation which may lead to prolonged stay in the ICU, including long term oxygen therapy and non-invasive ventilation not associated with sleep apnoea.
  • Patients mechanically ventilated in a ventilator mode, and by a ventilator not supported by the Beacon Caresystem on screening.
  • Respiratory failure likely requiring extracorporeal support.
  • Severe cardiogenic shock likely requiring extracorporeal support.
  • Severe isolated right heart failure.
  • Head trauma or other conditions where intra-cranial pressure may be elevated and tight regulation of arterial CO2 level is paramount.
  • Primary (non-overdose related) neurological patients (Glasgow coma score \<10, neurologic damage with limited prognosis, stroke hemiplegia).
  • End stage liver disease.
  • Repeated ICU admission within same hospital admission and/or likely to have prolonged ICU stay with mechanical ventilation (\>21 days)
  • Pregnancy.

About Royal Brompton & Harefield Nhs Foundation Trust

Royal Brompton & Harefield NHS Foundation Trust is a leading specialist healthcare provider in the United Kingdom, renowned for its expertise in cardiothoracic medicine and respiratory care. Committed to advancing clinical research and improving patient outcomes, the Trust conducts a diverse range of clinical trials aimed at exploring innovative treatments and therapies. With a multidisciplinary team of clinicians and researchers, the Foundation Trust fosters a collaborative environment that prioritizes patient safety and ethical standards, contributing significantly to the global body of medical knowledge and enhancing the quality of care for patients with complex health conditions.

Locations

London, , United Kingdom

Uxbridge, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Brijesh Patel, MBBS PhD

Principal Investigator

Royal Brompton & Harefield NHS Foundation Trust

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials